长春高新：关于子公司注射用GenSci143境外生产药品注册临床试验申请获得批准的公告

Core Viewpoint - Changchun High-tech announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., received written notification from the FDA approving the clinical trial application for the injectable GenSci143 [2] Group 1 - The approval from the FDA is a significant milestone for Changchun Jinsai Pharmaceutical, indicating progress in its drug development pipeline [2] - The injectable GenSci143 is expected to enhance the company's product offerings and potentially increase its market competitiveness [2]